Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  CEL-SCI Corporation    

CEL-SCI CORPORATION
Mes dernières consult.
Most popular
SummaryChartsNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

CEL SCI : Submits FDA Response for Its Phase 3 Head and Neck Cancer Trial

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/15/2017 | 08:03pm CEST

By a News Reporter-Staff News Editor at Cancer Weekly -- CEL-SCI Corporation (NYSE MKT: CVM) announced that it has responded to the U.S. Food and Drug Administration's (FDA) most recent communication from May 2017 about the clinical hold imposed on the Company's Phase 3 head and neck cancer study with Multikine* (Leukocyte Interleukin, Inj.) (see also Oncology - Head and Neck Cancer).

The hold issues addressed in the FDA communication were that the study's Investigator Brochure (IB) and the "Dear Investigator" letter need to be revised. Specific deficiencies and their locations in each of the documents were identified, and directions were given as to the specific information that should be included in the revisions of these documents. CEL-SCI revised the documents exactly as directed by the FDA. If the FDA finds the revisions made to the two documents to be satisfactory, CEL-SCI is hopeful that all of the clinical hold issues have now been addressed, and the FDA will consider lifting the clinical hold.

As of September 2016, nine hundred twenty-eight (928) head and neck cancer patients have been enrolled and have completed treatment in the Phase 3 study. In accordance with the study protocol, the FDA's instructions, and subject to the clinical hold, CEL-SCI continues to follow these patients.

Keywords for this news article include: CEL-SCI Corporation, Head and Neck Neoplasms, Oncology - Head and Neck Cancer, Government Agencies Offices and Entities.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CEL-SCI CORPORATION
10/13 CEL SCI : receives new European patent for investigational immunotherapy
10/12 CEL SCI : Announces Update on Ongoing Arbitration against Former Clinical Resear..
10/10 CEL SCI : NEW STORY CEL-SCI Granted European Patent for Multikine's Mechanism of..
10/10 CEL SCI : Granted European Patent for Multikine’s Mechanism of Action in M..
10/06 CEL SCI : Announces Update on Ongoing Arbitration against Former Clinical Resear..
10/06 CEL SCI CORP : Entry into a Material Definitive Agreement (form 8-K)
10/05 CEL SCI : NEW STORY CEL-SCI Announces Update on Ongoing Arbitration Against Form..
10/05 CEL SCI : Announces Update on Ongoing Arbitration against Former Clinical Resear..
09/28 CEL SCI : Announces $1.5 Million NIH SBIR Grant to Support Development of Rheuma..
09/20 CEL SCI : Announces $1.5 Million NIH SBIR Grant to Support Development of Rheuma..
More news
News from SeekingAlpha
06/12 CEL-SCI TO REVERSE SPLIT STOCK 1 : 25 June 15
06/06 CEL-SCI submits FDA response for its Phase 3 head and neck cancer trial
05/24 FDA places CEL-SCI's late-stage Multikine study in head and neck cancer on fu..
05/10 Cel-Sci reports Q2 results
04/28 CEL-SCI nabs new European patent covering Multikine; shares rally 41%
Chart CEL-SCI CORPORATION
Duration : Period :
CEL-SCI Corporation Technical Analysis Chart | US1508375086 | 4-Traders
Managers
NameTitle
Geert R. Kersten CEO, CFO, Director & Chief Accounting Officer
Patricia B. Prichep Secretary & Senior Vice President-Operations
Eyal Talor Chief Scientific Officer
Alexander G. Esterhazy Independent Director
Peter R. Young Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CEL-SCI CORPORATION15.33%22
GILEAD SCIENCES11.73%106 054
REGENERON PHARMACEUTICALS19.69%46 395
VERTEX PHARMACEUTICALS110.07%38 985
ACTELION23.81%29 840
GENMAB14.75%12 865